Proteomics flags US rollout of kidney test at global diabetes summit
- James Pearson
- Jun 20
- 3 min read
Updated: Jun 25
ASX-listed diagnostics disruptor Proteomics International (ASX: PIQ) has officially launched its innovative kidney disease test, PromarkerD, in the massive United States healthcare market.
The launch took place at the American Diabetes Association’s 85th scientific sessions talkfest in Chicago. The annual conference marks the world’s largest gathering of diabetes experts, making it the ideal stage to unveil PromarkerD to the US market.
PromarkerD is a simple predictive blood test capable of identifying a person’s risk of developing diabetic kidney disease (DKD) up to four years before symptoms appear, offering a potential lifeline to the more than 32 million Americans living with type 2 diabetes.
Proteomics has simplified earlier versions of the system to create a next-generation PromarkerD test that uses just two protein biomarkers to generate an accurate, personalised DKD risk score.
The company is now positioned for global commercialisation of its product and will expand its regulatory applications program, using its precision diagnostics approach to open new pathways to transform diabetic care.
According to its latest clinical study, the patented next-gen test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms, repeating the results achieved in earlier clinical trials.
More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation’s Medicare budget.
We’re excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.
Proteomics International Managing Director Dr Richard Lipscombe
The PromarkerD rollout will begin in California, supported by the company’s recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International’s integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement.
Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test “a paradigm shift in diabetes care.” Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.
Proteomics says the Chicago launch has fired the starting gun on a broader commercial strategy targeting licensing, distribution and health insurance partnerships across the US.
To support the push, the company plans to present fresh clinical evidence comparing PromarkerD’s performance against standard care, as part of the association’s Late Breaking Abstracts program – an initiative designed to deliver important and timely research developments.
The US rollout comes hot on the heels of PromarkerD’s Australian release three months ago, where the test was sold for the first time in a targeted campaign across Western Australia and the Northern Territory.
Proteomics says the domestic campaign gave it a perfect opportunity to fine-tune the company’s logistics and consumer engagement models in preparation for US expansion.
Backed by rigorous science and a clearly articulated path to market, Proteomics’ PromarkerD appears to be emerging as a flagship diagnostic tool in the fight against diabetic kidney disease.
Should the rollout prove successful, the test could change lives and reshape an entire segment of chronic disease management in the world’s most expensive healthcare system.
Is your ASX-listed company doing something interesting? Contact: office@bullsnbears.com.au
